A fullness signal and medical treatment, not magic fat burning
GLP-1 is a natural hormone released by the gut after eating and involved in glucose and appetite regulation. Medicines that mimic this signal act on appetite centres in the brain, increase fullness and slow stomach emptying. Some act at the GLP-1 receptor alone, while dual medicines act at both GLP-1 and GIP receptors. They are not insulin and do not directly dissolve fat; they can make an appropriate intake easier to sustain. Products are not interchangeable and should not be switched without the prescriber. [1, 3, 4]
Results vary with the medicine, dose, tolerance and health context. In STEP 1, mean weight change with semaglutide 2.4 mg was about 14.9% at 68 weeks, compared with 2.4% with placebo. In SURMOUNT-1, mean loss with tirzepatide ranged from 15% to 20.9% at 72 weeks according to dose, compared with 3.1% with placebo. These are trial averages from selected groups receiving lifestyle support, not a promised result or a target everyone must reach. [5, 6]
The medicine treats overweight or obesity and their health effects, not a rapid appearance change before an event. If you want to see where medication sits among other choices, non-surgical weight-management options summarises the broader pathways without moving into individual doses or brands. [1, 2]
Who may discuss treatment with a clinician?
The decision begins with diagnosing overweight or obesity and assessing their health effect. NIDDK notes that medicine may be considered for an adult with a BMI of 30 or above, or 27 or above with a weight-related condition such as hypertension or type 2 diabetes. These are a framework, not an automatic prescription. The clinician also considers waist measurement, glucose, blood pressure, lipids, sleep, liver and joint health, previous treatment and medicines that may promote weight gain. [1, 2]
The right medicine is not simply the 'strongest'. Diabetes, cardiovascular disease, kidney or liver problems, digestive symptoms, other medicines, pancreatic or gallbladder history and pregnancy plans may all change the choice. Administration, follow-up, tolerability and a realistic health goal matter too. Evidence for a particular benefit in one population does not apply to every person or product. [2, 3, 4]
Medicine need not be the first or only step. Some people benefit from nutrition and behavioural care without medication, others need medicine alongside it, and some require another pathway. Active eating-disorder symptoms, using an injection to avoid eating, or buying an unidentified product without a prescription call for clinical assessment. Shared decisions should clarify why treatment fits, the alternatives and how benefit will be judged. [1, 2]
Before the first dose: a targeted assessment, not a fixed test list
Before starting, list every diagnosis, medicine and supplement. Diabetes treatments matter because some combinations increase hypoglycaemia risk, while delayed gastric emptying may affect absorption of some oral medicines. Mention pancreatitis, gallbladder disease, kidney disease, recurrent vomiting, severe delayed stomach emptying, serious drug allergy or diabetic retinopathy. The current product label is the reference for warnings. [3, 4]
A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2, is a contraindication in the semaglutide and tirzepatide weight-management labels. This specific warning does not make every thyroid nodule or hypothyroidism equivalent. Give the clinician the precise diagnosis and family history. Routine calcitonin measurement or thyroid ultrasound has uncertain value; assessment follows symptoms and history. [3, 4]
There is no universal laboratory panel. The clinician may request HbA1c or fasting glucose, kidney or liver tests, lipids or other investigations according to clinical context. The purpose is to establish a baseline and detect something that changes the decision. Bring previous measurements, a medicine list and recent results. [1, 2]
Titration and common effects: escalation is not a race
These injections usually begin at a low dose and escalate over several weeks. Titration supports tolerability; the starting dose is not meant to produce maximum loss. Nausea, diarrhoea, vomiting, constipation, abdominal pain, bloating and reflux are common, often during escalation. The suitable dose is not necessarily the highest. Review persistent effects or inadequate intake before an increase. Do not combine related medicines, alter the dose, or restart high after a break on your own. [3, 4, 5, 6]
Smaller meals, slow eating, stopping at comfortable fullness and limiting rich meals when they worsen nausea may help. Take appropriate fluid, increase fibre gradually and use light movement when suitable. These steps do not replace assessment of severe symptoms. For a missed dose, follow that product's instructions or ask the pharmacist or clinician; never double it to compensate. [3, 4]
Follow-up should cover hunger, intake, bowel movements, vomiting, energy, dizziness and hypoglycaemia as well as weight, waist, blood pressure or agreed markers. Insufficient benefit or excessive effects may lead to holding, reducing, changing or stopping treatment with a plan. Adjustment is part of response-based care. [1, 2]
Red flags and situations to report promptly
Severe, persistent abdominal pain, particularly when it radiates to the back or comes with vomiting, needs urgent assessment for possible pancreatitis. Strong right-upper abdominal pain, jaundice or fever may indicate gallbladder disease. Persistent vomiting or diarrhoea with little urine or marked dizziness can cause dehydration and affect kidney function. Breathing difficulty, facial or tongue swelling, or a widespread rash after a dose is an emergency because of possible serious allergy. Do not treat severe pain or vomiting as proof that the medicine is 'working'; seek urgent care according to severity. [3, 4]
If you use insulin or a medicine that stimulates insulin release, discuss hypoglycaemia risk, monitoring and dose adjustment with the clinician; do not reduce treatment yourself. If you have diabetes and retinopathy, a rapid change in glucose control may require eye follow-up according to your situation. Before general anaesthesia, deep sedation or an endoscopic procedure, tell the anaesthesia and procedure teams the medicine name and last dose because delayed stomach emptying may increase the chance of retained stomach contents. The team decides fasting or dose instructions for the procedure and your circumstances; an internet rule cannot do that safely. [3, 4]
Weight-management medicines are not used during pregnancy, and pregnancy plans or breastfeeding must be discussed before prescribing. Discontinuation timing varies by active ingredient; for example, the current semaglutide label advises stopping at least two months before a planned pregnancy. Rather than covering every reproductive detail here, weight-loss medicines before pregnancy explains planning and a safer transition. If pregnancy occurs during treatment, withhold a further dose and contact the prescriber and obstetric clinician promptly so the next step can be decided without panic. [1, 3, 4]
In January 2026, the FDA said its comprehensive review did not identify an increased risk of suicidal thoughts or behaviour with GLP-1 medicines and requested removal of that specific warning from the relevant weight-management labels. This is an important correction, but it is not a reason to ignore a concerning mental-health change. New or worsening depression or thoughts of self-harm need urgent clinical help regardless of their cause. [9]
Less appetite must not mean neglecting nutrition and muscle
When appetite falls quickly, it is easy to pass the day on a few bites. That can reduce protein, fluid, fibre and micronutrients, worsen constipation and fatigue, and make training harder. The goal is not to lose all interest in food; it is to eat an appropriate amount with adequate quality. Use smaller meals when fullness is early, including a suitable protein source, vegetables or fruit and an energy source that fits the plan. Requirements change with body size, age, activity, kidney and liver health, so a protein number from a video is not a prescription for everyone. [1, 8]
Any weight loss can include some fat-free mass rather than fat alone. A scientific review of GLP-1-based therapies found wide variation among studies in the proportion of total loss described as lean mass; it also explained that 'lean mass' is not an exact synonym for muscle because it includes fluid, tissues and organs. One number should therefore neither be used to frighten people nor to declare that every body-composition change represents dangerous muscle loss. The trend is interpreted alongside strength, function, intake and hydration, with review if clear weakness or poorer performance develops. [8]
Resistance exercise suited to your ability signals that muscle is needed. Walking and aerobic activity support health, but do not fully replace resistance work. A starting point may use body weight, bands or light loads, progressing according to joint health, cardiovascular status and fitness. Sleep and recovery also matter; hard training alongside inadequate food and repeated vomiting is not a muscle-protection plan. For practical detail without repeating a neighbouring topic, see protecting muscle while losing weight, and report weakness, dizziness or a clear fall in strength to the treating team. [1, 8]
Discuss continuation and stopping from the beginning
For many people, obesity is chronic and can recur, while a medicine's effect on hunger and fullness fades after withdrawal. In the STEP 1 extension, participants who stopped semaglutide regained, on average, about two-thirds of their prior loss over the following year. In SURMOUNT-4, withdrawal of tirzepatide led to substantial weight regain, while continued treatment maintained and augmented loss in the trial group. These findings do not say that every person must continue forever, but they show why abrupt withdrawal without a plan may allow appetite and weight to return. Regaining some weight is not addiction or weak willpower; it is one reason obesity care often needs a long-term view. [7, 12]
Before starting, agree with the clinician on the health goal, review schedule, what counts as sufficient benefit and which effects require adjustment. Discuss possible continuation, change or stopping from the beginning, alongside food, movement, sleep and behavioural support through any transition. Do not stop because of one temporary scale reading, and do not continue through clear harm solely from fear of regain. The decision is individual and belongs in review with the prescriber, particularly when health, other medicines, pregnancy plans or the need for surgery or sedation changes. [1, 2, 3, 4]
If you are considering treatment or need to review an existing prescription, prepare the medicine name and strength, last dose, a full medicine list, recent results and a simple record of appetite, symptoms and weight. In clinic, assessment establishes whether medicine is appropriate at all, what follow-up is needed, and whether nutrition and muscle protection have a real place in the plan. There is no promise of a number or speed, and assessment may conclude that starting should wait or that another route fits better. When you need a structured decision with follow-up, you can request a weight-management consultation to discuss your circumstances with the clinical team. [1, 2]
